DOP2024000049A - Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos - Google Patents

Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos

Info

Publication number
DOP2024000049A
DOP2024000049A DO2024000049A DO2024000049A DOP2024000049A DO P2024000049 A DOP2024000049 A DO P2024000049A DO 2024000049 A DO2024000049 A DO 2024000049A DO 2024000049 A DO2024000049 A DO 2024000049A DO P2024000049 A DOP2024000049 A DO P2024000049A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
monocarboxylate transporter
human
mct1
human monocarboxylate
Prior art date
Application number
DO2024000049A
Other languages
English (en)
Inventor
Vladimirovna Rubtsova Kira
Charles Dorsey Frank
Benjamin Granger Joseph
Schroeder Oliver
Wang Wei
Original Assignee
Immunometabolism Dev Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunometabolism Dev Company Llc filed Critical Immunometabolism Dev Company Llc
Publication of DOP2024000049A publication Critical patent/DOP2024000049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con anticuerpos que se unen específicamente al transportador de monocarboxilato humano 1 (MCT1) (“anticuerpos anti-MCT1 humanos”), composiciones que comprenden dichos anticuerpos anti-MCT1 humanos y métodos para usar tales anticuerpos anti-MCT1 humanos.
DO2024000049A 2021-09-14 2024-03-12 Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos DOP2024000049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US202163272903P 2021-10-28 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000049A true DOP2024000049A (es) 2024-06-16

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000049A DOP2024000049A (es) 2021-09-14 2024-03-12 Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos

Country Status (15)

Country Link
US (1) US11987624B2 (es)
EP (1) EP4402172A1 (es)
JP (1) JP2023542639A (es)
KR (1) KR20240053656A (es)
AU (1) AU2022347031A1 (es)
CA (1) CA3230072A1 (es)
CL (1) CL2024000733A1 (es)
CO (1) CO2024003042A2 (es)
CR (1) CR20240133A (es)
DO (1) DOP2024000049A (es)
EC (1) ECSP24020235A (es)
IL (1) IL311253A (es)
MX (1) MX2024003115A (es)
TW (1) TWI842088B (es)
WO (1) WO2023044325A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
EP2723393A4 (en) 2011-06-24 2015-02-25 Ct Se Llc EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
AU2019205489A1 (en) * 2018-01-05 2020-06-25 Amgen, Inc. Anti-MCT1 antibodies and uses thereof

Also Published As

Publication number Publication date
AU2022347031A1 (en) 2024-03-14
EP4402172A1 (en) 2024-07-24
ECSP24020235A (es) 2024-06-28
WO2023044325A1 (en) 2023-03-23
CO2024003042A2 (es) 2024-03-18
MX2024003115A (es) 2024-06-19
CR20240133A (es) 2024-05-06
CL2024000733A1 (es) 2024-08-30
JP2023542639A (ja) 2023-10-11
WO2023044325A9 (en) 2024-04-25
US20230111363A1 (en) 2023-04-13
TWI842088B (zh) 2024-05-11
US11987624B2 (en) 2024-05-21
TW202330602A (zh) 2023-08-01
KR20240053656A (ko) 2024-04-24
IL311253A (en) 2024-05-01
CA3230072A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
CO2021004560A2 (es) Anticuerpos estabilizadores de trem2
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2020012415A2 (es) Anticuerpos de unión a vista a ph ácido
EA202092202A1 (ru) Конструкции антител к ror
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
PE20210687A1 (es) Anticuerpos de union a vista a ph acido
CO2023017156A2 (es) Anticuerpos anti-sirp-alfa
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
EA202190888A1 (ru) Пептид для применения в косметике
CL2024001304A1 (es) Anticuerpos anti-cd19 humano
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
EA201992883A1 (ru) АНТИТЕЛА К TrkB
DOP2024000049A (es) Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos
ECSP22004680A (es) Anticuerpos anti-angpt2
CU20200015A7 (es) Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
CO2023009885A2 (es) Antagonistas de gitr y métodos de uso de los mismos
AR123050A1 (es) ANTICUERPOS ANTI-Ab